A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Sickle Cell Disease Clinical Trial

Official title:

A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00834899
• Other study ID #: 1R21HL091265-01A1
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: January 31, 2009
• Last updated: May 22, 2013
• Start date: January 2009
• Est. completion date: March 2012

Study information

• Verified date: February 2013
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.

Description:

Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. Despite the abundant laboratory evidence of abnormal blood clotting and inflammation, the contribution of these changes to the problems experienced by patients with sickle cell disease remains uncertain. In additional to abnormal blood clotting, platelets (small blood cells that help blood clotting) are more activated in sickle cell disease patients compared to healthy patients without this disease.

In addition, when sickle cell disease patients experience a painful crisis, there is evidence that the platelet activation and abnormal blood clotting increase even further. Activated platelets release a substance called cluster of designation 40 ligand, which can increase how sticky the lining of blood vessels are and can increase the abnormal blood clotting. The level of cluster of designation 40 ligand is much higher in sickle cell disease patients compared to healthy individuals without this disease. In addition, the levels increase even further when sickle cell patients are experiencing a painful crisis.

Painful crisis represent the most common clinical problem in sickle cell disease, and are largely responsible for making the lives of these patients so unpredictable. However, the treatment of these painful crisis remains inadequate, consisting mainly of strong pain medications. In this study, we will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. At the completion of this trial, we will have an improved understanding of the contribution of platelet activation and inflammation to the problems in sickle cell disease.

The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. We believe that by decreasing platelet stickiness, and the release of mediators of inflammation and abnormal blood clotting, eptifibatide will affect the clinical course of complications in this disease.

If the results from our study support the hypothesis that eptifibatide is safe and effective in this population, we plan on carrying out larger studies to more definitively evaluate the safety of eptifibatide and how well it works in the treatment and/or prevention of painful crises in sickle cell disease.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: March 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Age between 18 and 55 years

2. Have confirmed diagnosis of sickle cell anemia or sickle beta zero thalassemia

3. Have a serum creatinine </= 1.2 mg/dl

4. Have serum transaminase values < 3 times upper limits of normal

5. Have a platelet count >/= 150 x 10^9/L

6. Have normal baseline coagulation profile

7. Sudden onset of pain involving one or more sites and typical of usual pain episodes

8. Have adequate intravenous access

9. Be able to understand the requirements of the study and be willing to give informed consent

10. Women of child-bearing age must be practicing (and will continue to practice for the course of the study) an adequate method of contraception (oral contraception, depo-provera, bilateral tubal ligation or barrier method)

Exclusion Criteria:

1. Have a baseline hemoglobin < 6.0 gm/dl

2. Have a history of major gastrointestinal bleeding or a bleeding diathesis

3. Have an ongoing episode of acute chest syndrome

4. Have a past history of clinically overt stroke(s)

5. Have severe hypertension (systolic blood pressure > 200mmHg and/or diastolic BP >110mmHg) not adequately controlled on hypertensive medication

6. Have had major surgery within the six weeks preceding enrollment

7. Are pregnant or breastfeeding

8. Are on chronic anticoagulation or antiplatelet (including non-steroidal anti-inflammatory drugs) therapy

9. Have a history of metastatic cancer

10. Are on a chronic transfusion program or have received a blood transfusion in the prior 8 weeks

11. Have a positive urine toxicology screen for phencyclidine, cocaine or amphetamines.

12. Have a history of alcohol abuse

13. Have received any investigational drugs within the past 4 weeks.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Eptifibatide
Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
• Placebo
Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.

Locations

Country	Name	City	State
United States	University of North Carolina	Chapel Hill	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1) Major Bleeding Episodes	Major bleeding episodes are defined as any episode, such as gastrointestinal bleeding or intracranial bleed that typically leads to hospitalization or other prolonged bleeding requiring a blood transfusion	Up to 35 days	Yes
Primary	Change in Platelet Count	Change in platelet counts occurring anytime from randomization up to day 35 (final follow-up visit).	Up to 35 days	Yes
Secondary	Effect of Eptifibatide on Duration of Acute Pain Episodes	The duration of the pain episode will be defined as the time from randomization to termination of the pain episode. The pain episode will be considered terminated when the patient states that the crisis is resolved (defined as being ready to go home on oral analgesics) or all of the following criteria are met: Pain relief (pain scores = 40) maintained for at least 2 consecutive readings (assessed using a visual analog scale with measurements from 0 - 100, where 0 is no pain and 100 is worst imaginable pain).; No parenteral analgesics have been administered for at least 12 hours.; Ability to walk normally (unless he/she was unable to walk for some other reason prior to the crisis onset).	Up to 7 days	No
Secondary	Effect of Eptifibatide on Duration of Hospitalization	The duration of hospitalization will be defined as the period from randomization to the time an order for discharge from the hospital is written.	Up to 7 days	No